Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 19/20 | 0.82 |
| ▸ | CNR1 | P21554 | 1/20 | 0.61 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2681384 | 0.90 | FAAH (1.00) | FAAHCNR1ACHEPDE4APDE4B | |
| SCHEMBL2681410 | 0.85 | FAAH (0.85) | FAAHCNR1ACHEPDE4APDE4B | |
| SCHEMBL1728639 | 0.85 | FAAH (0.85) | FAAHCNR1ACHEPDE4APDE4B | |
| SCHEMBL2682610 | 0.80 | FAAH (0.81) | FAAHCNR1ACHEPDE4APDE4B | |
| SCHEMBL5531371 | 0.79 | FAAH (1.00) | FAAHCNR1ACHEPDE4APDE4B | |
| SCHEMBL8004670 | 0.78 | FAAH (0.54) | FAAHCNR1ACHEPDE4APDE4B | |
| SCHEMBL5531322 | 0.78 | FAAH (1.00) | FAAHCNR1ACHEPDE4APDE4B | |
| SCHEMBL5533061 | 0.78 | FAAH (1.00) | FAAHCNR1ACHEPDE4APDE4B | |
| Trifluoroacetic Acid SCHEMBL2682623 | 0.77 | FAAH (0.91) | FAAHCNR1ACHEPDE4APDE4B | |
| SCHEMBL1002928 | 0.77 | FAAH (0.58) | FAAHCNR1ACHEPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8664253-B2 | Imidazole derivatives useful as modulators of FAAH and as FAAH imaging agents | MERCK SHARP & DOHME CORP (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | MERCK SHARP & DOHME CORP. | 2013-01-31 | — | — | US | disclosed |
| US-20120115894-A1 | IMIDAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH AND AS FAAH IMAGING AGENTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115894-A1 | IMIDAZOLE DERIVATIVES USEFUL AS MODULATORS OF FAAH AND AS FAAH IMAGING AGENTS | FAAH, FAAH2, INMT | FAAH 1/4885CNR1 17/4885ACHE 64/4885 |
| US-20130030000-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | FAAH, FAAH2, CNR2 | FAAH 1/4885CNR1 14/4885ACHE 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.